Amgen 1Q10 1Q Revenues: $3.5 billion (+9%) 1Q Earnings: $1.2 billion (+14%) Comments: U.S. sales rose 7% to $2.7 billion, while international sales were up 16% to $851 million, including an 8% boost from currency fluctuations. Aranesp sales were flat at $627 million, including an 8% drop in the U.S. Epogen sales rose 10% to $623 million. Neulasta/Neupogen combined sales rose 10% to $1.2 billion. Enbrel sales were up 6% to $804 million, and Sensipar revenues jumped 21% to $179 million....